Abstract
Our previous studies have shown that seven out of 15 patients with adrenocortical tumours contained K- ras gene mutation. In addition, the mutation type was a multiple-site mutation, and the hot spots were located at codons 15, 16, 18 and 31, which were different from those reported before (codons 12, 13 and 61). To understand whether the mutation hot spots in human adrenocortical tumours were associated with activation of K- Ras oncogene and the alterations of its biocharacteristics, mutant K- Ras genes were cloned from tumour tissues and then constructed with expression vector pBKCMV. Mutant K- Ras genes were expressed at high levels in Escherichia coli and the resultant K- Ras proteins were shown to be functional with respect to their well-known specific, high-affinity, GDP/GTP binding. The purified K- Ras protein from E. coli were then measured for their intrinsic GTPase activity and the GTPase activity in the presence of GTPase-activating protein for Ras. The results showed that the wild-type cellular K- Ras protein (p21BN) exhibits about ten times higher intrinsic GTPase activity than the activated protein (p21BM3) encoded by mutant K- Ras gene, which mutated at codon 60. With regards to the codon 15, 16, 18 and 31 mutant K- Ras proteins (p21BM2), the GTPase activity in the presence of GAP is much lower than that of the normal K- Ras protein, whereas the intrinsic GTPase activity is nearly the same as that of the normal K- Ras protein. These results indicated that mutations at these hot spots of K- Ras gene were indeed activated K- Ras oncogene in adrenocortical tumours; however, their association with tumors needs further experiments to prove. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adari H, Lowy DR, Willumsen BM, Der CJ and McCormick F (1988) Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science 240: 518–521
Ahmadian MR, Wiesmuller L, Lautwein A, Bischoff FR and Wittinghofer A (1996) Structural differences in the minimal catalytic domains of the GTPase-activating proteins p120GAP and neurofibromin. J Biol Chem 271: 16409–16415
Anker P, Lefort F, Vasioukhin V, Lyautey J, Lederrey C, Chen XQ, Stroun M, Mulcahy HE and Farthing MJ (1997) K- ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 112: 1114–1120
Barbacid M (1987) Ras gene. Ann Rev Biochem 56: 779–827
Boriack-Sjodin PA, Margarit SM, Bar-Sagi D and Kuriyan J (1998) The structural basis of the activation of Ras by Sos [see comments]. Nature 394: 337–343
Caduff RF, Svoboda-Newman SM, Ferguson AW, Johnston CM and Frank TS (1999) Comparison of mutations of Ki-Ras and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol 23: 323–328
Capon DJ, Seeburg PH, McGrath JP, Hayflick JS, Edman U, Levinson AD and Goeddel DV (1983) Activation of Ki- ras 2 gene in human colon and lung carcinomas by two different point mutations. Nature 304: 507–513
Chen Q, Lin TH, Der CJ and Juliano RL (1996) Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras. (Published erratum appears in J Biol Chem 1996 271: 22280.). J Biol Chem 271: 18122–18127
Downward J (1996) Control of ras activation. Cancer Surv 27: 87–100
Feliciello A, Giuliano P, Porcellini A, Garbi C, Obici S, Mele E, Angotti E, Grieco D, Amabile G, Cassano S, Li Y, Musti AM, Rubin CS, Gottesman ME and Avvedimento EV (1996) The v-Ki- Ras oncogene alters cAMP nuclear signaling by regulating the location and the expression of cAMP-dependent protein kinase II beta. J Biol Chem 271: 25350–25359
Gao HG, Chen JK, Stewart J, Song B, Rayappa C, Whong WZ and Ong T (1997) Distribution of p53 and K- ras mutations in human lung cancer tissues. Carcinogenesis 18: 473–478
Grendys EC Jr, Barnes WA, Weitzel J, Sparkowski J and Schlegel R (1997) Identification of H-, K-, and N- ras point mutations in stage IB cervical carcinoma. Gynecol Oncol 65: 343–347
Gross M, Sweet RW, Sathe G, Yokoyama S, Fasano O, Goldfarb M, Wigler M and Rosenberg M (1985) Purification and characterization of human H-Ras proteins expressed in Escherichia coli. Mol Cell Biol 5: 1015–1024
Guan KL and Dixon JE (1991) Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal Biochem 192: 262–267
Hattori S, Maekawa M and Nakamura S (1992) Identification of neurofibromatosis type I gene product as an insoluble GTPase-activating protein toward ras p21. Oncogene 7: 481–485
Hughes PE, Renshaw MW, Pfaff M, Forsyth J, Keivens VM, Schwartz MA and Ginsberg MH (1997) Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 88: 521–530
Lautenberger JA, Ulsh L, Shih TY and Papas TS (1983) High level expression in Escherichia coli of enzymatically active Harvey murine sarcoma virus p21Ras protein. Science 221: 858–860
Leitner JW, Kline T, Carel K, Goalstone M and Draznin B (1997) Hyperinsulinemia potentiates activation of p21Ras by growth factors. Endocrinology 138: 2211–2214
Leon J, Guerrero I and Pellicer A (1987) Differential expression of the ras gene family in mice. Mol Cell Biol 7: 1535–1540
Lim HH, Michael GJ, Smith P, Lim L and Hall C (1992) Developmental regulation and neuronal expression of the mRNA of rat n-chimaerin, a p21rac GAP:cDNA sequence. Biochem J 287: 415–422
Lim L, Manser E, Leung T and Hall C (1996) Regulation of phosphorylation pathways by p21 GTPases. The p21 Ras-related Rho subfamily and its role in phosphorylation segralling pathways. Eur J Biochem 242: 171–185
Lin SR, Tsai JH, Yang YC and Lee SC (1998) Mutations of K- ras oncogene in human adrenal tumors in Taiwan. Br J Cancer 77: 1060–1065
Lin SR, Hsu CH, Tsai JH and Wang JY (1999). Effect of K- ras mutant derived from human primary aldosteronism on normal adrenocortical cells,
Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, Conroy L, Clark R, O’Connell P and Cawthon RM (1990) The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63: 843–849
Miao W, Eichelberger L, Baker L and Marshall MS (1996) p120 Ras GTPase-activating protein interacts with Ras-GTP through specific conserved residues. J Biol Chem 271: 15322–15322
Molloy DP, Owen D and Grand RJ (1995) Ras binding to a C-terminal region of GAP. FEBS Lett 368: 297–303
Mulcahy HE, Lyautey J, Lederrey C, Chen X, Anker P, Alstead EM, Ballinger A, Farthing MJ and Stroun M (1998) A prospective study of K- ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 4: 271–275
Nur-E-Kamal MS and Maruta H (1992) The role of Gln61 and Glu63 of Ras GTPases in their activation by NF1 and Ras GAP. Mol Biol Cell 3: 1437–1442
Overbeck AF, Brtva TR, Cox AD, Graham SM, Huff SY, Khosravi-Far R, Quilliam LA, Solski PA and Der CJ (1995) Guanine nucleotide exchange factors: activators of Ras superfamily proteins. Mol Reprod Dev 42: 468–476
Pells S, Divjak M, Romanowski P, Impey H, Hawkins NJ, Clarke AR, Hooper ML and Williamson DJ (1997) Developmentally-regulated expression of murine K- ras isoforms. Oncogene 15: 1781–1786
Porras A and Santos E (1996) The insulin/Ras pathway of adipocytic differentiation of 3T3 L1 cells: dissociation between Raf-1 kinase and the MAPK/RSK cascade. Int J Obes Relat Metab Disord 20: S43–51
Powers S, O’Neill K and Wigler M (1989) Dominant yeast and mammalian Ras mutations that interfere with the CD23-dependent activation of wild-type RAS in Saccharomyces cerevisiae. Mol Cell Biol 9: 390–395
Santos E and Nebreda AR (1989) Structural and functional properties of ras proteins. FASEB J 3: 2151–2163
Segal M, Willumsen BM and Levitzki A (1993) Residues crucial for Ras interaction with GDP-GTP exchangers. Proc Natl Acad Sci USA 90: 5564–5568
Shirozu M, Fujita-Yoshigaki J, Ito Y, Koide H, Nishimura S and Yokoyama S (1992) A glutamic acid residues at position 31 of Ras protein is essential to the signal transduction for neurite outgrowth of PC12 cells and the stimulation of GTPase activity by GAPRas. Oncogene 7: 475–480
Slamon DJ and Cline MJ (1984) Expression of cellular oncogenes binding embryonic and fetal development of the mouse. Proc Natl Acad Sci USA, 7141–7145
Sung YJ, Carter M, Zhong JM and Hwang YW (1995) Mutagenesis of the H- Ras p21 at glycine-60 residue disrupts GTP-induced conformational change. Biochemistry 34: 3470–3477
Vogel US, Dixon RAF, Schaber MD, Diehl RE, Marshall MS, Scolnick EM, Signal IS and Gibbs JB (1988) Cloning of bovine GAP and its interaction with oncogenic ras p21. Nature 335: 90–93
Winston LA and Hunter T (1995) JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. J Biol Chem 270: 30837–30840
Wittinghofer A, Scheffzek K and Ahmadian MR (1997) The interaction of Ras with GTPase-activating proteins. FEBS Lett 410: 63–67
Xu GF, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, White R, Weiss R and Tamanoi F (1990) The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63: 835–841
Yamashita N, Minamoto T, Ochiai A, Onda M and Esumi H (1995) Frequent and characteristic K-ras activation in aberrant crypt foci of colon. Is there preference among K- ras mutants for malignant progression? Cancer 75: 1527–1533
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Lin, SR., Hsu, CH., Tsai, JH. et al. Decreased GTPase activity of K- ras mutants deriving from human functional adrenocortical tumours. Br J Cancer 82, 1035–1040 (2000). https://doi.org/10.1054/bjoc.1999.1039
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1039